This company has been acquired
BLU Stock Overview
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BELLUS Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$19.50 |
| 52 Week High | CA$19.90 |
| 52 Week Low | CA$8.58 |
| Beta | -0.28 |
| 1 Month Change | -1.42% |
| 3 Month Change | 100.82% |
| 1 Year Change | 50.70% |
| 3 Year Change | 38.79% |
| 5 Year Change | 962.09% |
| Change since IPO | -97.95% |
Recent News & Updates
Recent updates
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans
Jan 16
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
Sep 07We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely
May 05Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation
Jan 06Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth
Sep 10Shareholder Returns
| BLU | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0.5% | -3.3% | -2.0% |
| 1Y | 50.7% | 12.9% | 15.2% |
Return vs Industry: BLU exceeded the Canadian Biotechs industry which returned 23.5% over the past year.
Return vs Market: BLU exceeded the Canadian Market which returned 0.8% over the past year.
Price Volatility
| BLU volatility | |
|---|---|
| BLU Average Weekly Movement | 28.1% |
| Biotechs Industry Average Movement | 13.5% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: BLU's share price has been volatile over the past 3 months.
Volatility Over Time: BLU's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 74 | Roberto Bellini | www.bellushealth.com |
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Inc. Fundamentals Summary
| BLU fundamental statistics | |
|---|---|
| Market cap | CA$2.47b |
| Earnings (TTM) | -CA$115.02m |
| Revenue (TTM) | CA$19.88k |
Over9,999x
P/S Ratio-21.5x
P/E RatioIs BLU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLU income statement (TTM) | |
|---|---|
| Revenue | US$15.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.00k |
| Other Expenses | US$86.80m |
| Earnings | -US$86.79m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -578,586.67% |
| Debt/Equity Ratio | 0% |
How did BLU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/28 12:28 |
| End of Day Share Price | 2023/06/28 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Justin Zelin | BTIG |
| Pooya Hemami | Edison Investment Research |